Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

South Korea's trade minister Yeo Han-koo will visit the United States from June 22 to 27, the trade ministry said on Saturday ...